HCWB Stock — HCW Biologics Inc.

HCW Biologics Inc. (HCWB)

Updated October 16, 2026.

HCWB is a Stock. Total return is -99.9% over the past 5.2 years, 189.8 points behind SPY at 89.9%.

HCW Biologics Inc. is a clinical-stage biopharmaceutical company developing novel immunotherapies focused on chronic, low-grade inflammation and related diseases, with a pipeline including T-cell engagers, fusion molecules combining cytokines with checkpoint inhibitors, and IL-2 fusion proteins in clinical trials. The company does not currently have an established distribution schedule. This security appeals to investors seeking exposure to early-stage biotechnology development, though it carries the substantial risk profile typical of clinical-stage companies without approved products or revenue.

HCWB performance versus SPY

Price and return data through 2026-10-16.

Total return is -99.9% over the past 5.2 years, 189.8 points behind SPY at 89.9%. Over the past year its total return — price change plus distributions reinvested — is -94.9%. Its deepest 1-year drawdown was 95.1%.

HCWB key facts

Asset type

Stock

Asset class

Equity

Inception date

07/20/2021

Distribution frequency

None

Last close

$1.24 (as of 2026-10-16)

Market cap

$2,773,042

Average volume

77645.0

Beta

2.419

Payout ratio

0.0%

EPS

$-18.74

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

HCWB risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 95.1%.

Who may consider HCWB — and who may not

It is a weaker fit for investors who need monthly cash flow (HCWB does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on HCWB

• All tickers starting with H

Tagged: Healthcare.

Frequently asked questions